NanoViricides licenses coronavirus drug field from TheraCour; no upfront cash

NANOVIRICIDES, INC.

Exclusive worldwide license for coronavirus antiviral drugs; no upfront cash payment to TheraCour.
Milestone payments include up to 750,000 Series A preferred shares and up to $11M in cash tied to clinical development.
Royalty of 15% on net sales of licensed products; TheraCour retains manufacturing rights.
President Anil Diwan's employment extended to June 30, 2022 with $400K base salary and 10,204 Series A shares vesting quarterly.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.